Matinas Biopharma Holdings Inc., of Bedminster, N.J., commenced dosing in the first-in-human study of MAT9001. The company's initial trial is being conducted in Canada and is a pharmacokinetic and pharmacodynamic study of MAT9001 vs. an active comparator.